One of the major advantages of CNT-FET biosensors is their ability to detect a wide range of biomolecules, including proteins, DNA, and viruses. Additionally, CNT-FET biosensors can be easily integrated with microfluidic devices, allowing for the continuous monitoring of biological samples. CNT-FET biosensors also have the potential to be used for the early diagnosis of diseases, such as AD, as well as for related drug discovery and development. Despite their promising applications, CNT-FET biosensors still face some challenges, such as the reproducibility of the nanotube synthesis and functionalization, as well as the selectivity and specificity of the biosensing process. However, ongoing research in this field is focused on addressing these challenges and improving the performance and reliability of CNT-FET biosensors. However, using nano-FET biosensors for blood-based biomarker detection in a clinical setting is still difficult due to the lack of cost-effective mass production for high-performance nano-FET platforms, and the wafer-scale preparation of FETs with high uniformity is not feasible for most nanomaterial-based FET sensors.